Biomea Fusion (BMEA) director granted 196,299 stock options at $1.15 exercise price

Rhea-AI Filing Summary

Biomea Fusion, Inc. director Elizabeth Faust received a grant of stock options covering 196,299 shares of common stock at an exercise price of $1.15 per share. These options vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual stockholder meeting, contingent on her continued service. Following this grant, she holds 196,299 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Faust Elizabeth

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	196,299	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 196,299 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 196,299 options Exercise price: $1.15 per share Underlying shares: 196,299 shares +2 more

5 metrics

Stock options granted 196,299 options Grant reported on Form 4

Exercise price $1.15 per share Conversion or exercise price of options

Underlying shares 196,299 shares Common stock underlying the options

Post-transaction derivative holdings 196,299 options Total derivative securities following transaction

Option expiration Expires 2036-06-09 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, derivative securities, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "1.1500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative securities financial

"derivativeTransactionCount for all derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vest in full financial

"The shares underlying the stock option will vest in full upon the earlier of..."

annual meeting of the Issuer's stockholders financial

"immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faust Elizabeth

(Last) (First) (Middle)

C/O BIOMEA FUSION, INC.

1599 INDUSTRIAL ROAD

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Biomea Fusion, Inc. [ BMEA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.15	06/10/2026		A		196,299		(1)	06/09/2036	Common Stock	196,299	$0	196,299	D

Explanation of Responses:

1. The shares underlying the stock option will vest in full upon the earlier of (i) the one-year anniversary of the date of grant or (ii) immediately prior to the annual meeting of the Issuer's stockholders that occurs following the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.

	/s/ Rainer Erdtmann as Attorney-in-Fact for Elizabeth Faust	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Biomea Fusion (BMEA) director Elizabeth Faust report on this Form 4?

Elizabeth Faust reported receiving a grant of stock options for 196,299 shares of Biomea Fusion common stock. The award is a compensation-related acquisition, not an open-market purchase or sale, and is structured as a Stock Option (Right to Buy) at a fixed exercise price.

How many Biomea Fusion (BMEA) shares are covered by the new stock options?

The new stock option grant covers 196,299 shares of Biomea Fusion common stock. These shares are underlying derivative securities, giving the director the right to buy at a preset exercise price if the options vest and are later exercised.

What is the exercise price of the Biomea Fusion (BMEA) stock options granted to Elizabeth Faust?

The stock options granted to Elizabeth Faust have an exercise price of $1.15 per share. This means she can purchase Biomea Fusion common stock at $1.15 per share upon exercising the options after they vest, regardless of the then-current market price.

When do the newly granted Biomea Fusion (BMEA) stock options vest?

The options will vest in full on the earlier of the one-year anniversary of the grant date or immediately before the next annual meeting of stockholders. Vesting is conditioned on the director’s continued service to Biomea Fusion through the applicable vesting date.

How many derivative securities does Elizabeth Faust hold after this Biomea Fusion (BMEA) transaction?

After the reported transaction, Elizabeth Faust holds 196,299 derivative securities in the form of stock options. This total matches the number of options granted in the filing and reflects her direct beneficial ownership following the grant acquisition.

Is this Biomea Fusion (BMEA) Form 4 a market buy or sell by the director?

No. The Form 4 reflects a grant or award acquisition of stock options, coded as “A” for grant, award, or other acquisition. There were no open-market purchases or sales of Biomea Fusion common stock reported in this specific filing.